TY - JOUR
TI - The expression of C-myc, tenascin and HER-2/neu in uterine sarcomas and its relation to clinical outcome
AU - Zafeiriou, S.
AU - Papadimitriou, C.
AU - Markaki, S.
AU - Pavlou, B.
AU - Voulgaris, Z.
AU - Rodolakis, A.
AU - Vlachos, G.
AU - Diakomanolis, E.
AU - Zervoudis, S.
AU - Antsaklis, A.
AU - Schindler, A.E.
JO - Tumor Diagnostik und Therapie
PY - 2007
VL - 28
TODO - 4
SP - 184-189
PB - 
SN - null
TODO - 10.1055/s-2007-963240
TODO - epidermal growth factor receptor 2;  Myc protein;  tenascin, cancer recurrence;  cancer survival;  clinical article;  controlled study;  female;  gene expression;  human;  immunohistochemistry;  leiomyosarcoma;  Muellerian duct;  oncogene c myc;  protein expression;  review;  uterus sarcoma
TODO - Introduction: The purpose of this study was to evaluate the expression of oncogenes C-myc, HER-2/neu and the extracellular matrix glucoprotein Tenascin in uterine sarcomas and its relation to clinical outcome (survival and recurrence rates). Patients or Methods: 36 patients with uterine sarcomas participated in the study, where 22 suffered from mixed mullerian tumors, 10 from leiomyosarcoma and 4 from other types. C-myc, Tenascin and HER-2/neu expression was evaluated in all 36 cases by the use of immunochistochemical procedures. Results: C-myc was positive in 23 out at 36 cases (64%), Tenascin in 15 out at 36 cases (42%), and HER/2-neu in 8 out at 36 cases (22%). Survival and recurrence rates were not found to differ significantly between positive or negative expression of all three substances of our study. Conclusion: In the 36 uterine sarcomas of the present study (22 mixed mullerian tumors, 10 leiomyosarcomas and 4 other types), expression of any of the 3 proteins investigated is not associated with increased/decreased survival or recurrence. © Georg Thieme Verlag KG Stuttgart.
ER -